TRVI - Trevi Therapeutics, ...

Discounted Cash Flow Model Levered of Trevi Therapeutics, Inc.(TRVI), Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and

Trevi Therapeutics, Inc.

TRVI

NASDAQ

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

2.58 USD

-0.085 (-3.29%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

FMP

Home Terms of Service Privacy Policy Blog Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.